185 related articles for article (PubMed ID: 38096958)
21. Acetyltanshinone IIA reduces the synthesis of cell cycle-related proteins by degrading p70S6K and subsequently inhibits drug-resistant lung cancer cell growth.
Huang B; Hao M; Li C; Luo KQ
Pharmacol Res; 2022 May; 179():106209. PubMed ID: 35398238
[TBL] [Abstract][Full Text] [Related]
22. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
23. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update.
Roskoski R
Pharmacol Res; 2024 Feb; 200():107059. PubMed ID: 38216005
[TBL] [Abstract][Full Text] [Related]
24. Identification of new MRP4 inhibitors from a library of FDA approved drugs using a high-throughput bioluminescence screen.
Cheung L; Yu DM; Neiron Z; Failes TW; Arndt GM; Fletcher JI
Biochem Pharmacol; 2015 Feb; 93(3):380-8. PubMed ID: 25462817
[TBL] [Abstract][Full Text] [Related]
25. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research.
Dong RF; Zhu ML; Liu MM; Xu YT; Yuan LL; Bian J; Xia YZ; Kong LY
Pharmacol Res; 2021 May; 167():105583. PubMed ID: 33775864
[TBL] [Abstract][Full Text] [Related]
26. The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.
Roskoski R
Pharmacol Res; 2020 May; 155():104725. PubMed ID: 32109580
[TBL] [Abstract][Full Text] [Related]
27. Irinotecan: 25 years of cancer treatment.
Bailly C
Pharmacol Res; 2019 Oct; 148():104398. PubMed ID: 31415916
[TBL] [Abstract][Full Text] [Related]
28. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
29. Targeting ERK1/2 protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Apr; 142():151-168. PubMed ID: 30794926
[TBL] [Abstract][Full Text] [Related]
30. The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.
Roskoski R
Pharmacol Res; 2018 Jul; 133():35-52. PubMed ID: 29704617
[TBL] [Abstract][Full Text] [Related]
31. Targeting Akt/PKB in pediatric tumors: A review from preclinical to clinical trials.
Toson B; Fortes IS; Roesler R; Andrade SF
Pharmacol Res; 2022 Sep; 183():106403. PubMed ID: 35987481
[TBL] [Abstract][Full Text] [Related]
32. A Computer - Aided Drug Designing for Pharmacological Inhibition of Mutant ALK for the Treatment of Non-small Cell Lung Cancer.
Sharda S; Khandelwal R; Adhikary R; Sharma D; Majhi M; Hussain T; Nayarisseri A; Singh SK
Curr Top Med Chem; 2019; 19(13):1129-1144. PubMed ID: 31109278
[TBL] [Abstract][Full Text] [Related]
33. New frontiers against sorafenib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers.
He Y; Luo Y; Huang L; Zhang D; Wang X; Ji J; Liang S
Pharmacol Res; 2021 Aug; 170():105732. PubMed ID: 34139345
[TBL] [Abstract][Full Text] [Related]
34. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
Roskoski R
Pharmacol Res; 2021 Oct; 172():105806. PubMed ID: 34450320
[TBL] [Abstract][Full Text] [Related]
35. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
Roskoski R; Sadeghi-Nejad A
Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
[TBL] [Abstract][Full Text] [Related]
36. Should we keep rocking? Portraits from targeting Rho kinases in cancer.
de Sousa GR; Vieira GM; das Chagas PF; Pezuk JA; Brassesco MS
Pharmacol Res; 2020 Oct; 160():105093. PubMed ID: 32726671
[TBL] [Abstract][Full Text] [Related]
37. Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms.
Roskoski R
Pharmacol Res; 2016 Nov; 113(Pt A):395-408. PubMed ID: 27641927
[TBL] [Abstract][Full Text] [Related]
38. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
[TBL] [Abstract][Full Text] [Related]
39. Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease.
Sahoo AK; Dandapat J; Dash UC; Kanhar S
J Ethnopharmacol; 2018 Apr; 215():42-73. PubMed ID: 29248451
[TBL] [Abstract][Full Text] [Related]
40. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes.
Roskoski R
Pharmacol Res; 2016 Jan; 103():26-48. PubMed ID: 26529477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]